1:37 am Gilead Sciences announces Phase 2 results for two investigational all-oral sofosbuvir-based regimens for the treatment of Chronic Hepatitis C
View todays social media effects on GILD
View the latest stocks trending across Twitter. Click to view dashboard
See who Gilead is hiring next, click here to view
